• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Alkem’s St Louis facility gets two observations from US FDA

expresspharmaJune 21, 2021

Tag: FDA , Alkem , facility

Alkem Laboratories informed that the US FDA has issued Form 483 with two observations for its manufacturing facility located in St Louis, US. The US FDA had conducted an inspection of the company’s manufacturing facility from 14-18, June 2021.

The company also informed that it will submit to US FDA within the stipulated timeline, a detailed response to close out all the observations associated with this inspection.

Previous:Study shows corticosteroids may be effective in treating COVID-19 complications in children

Next:Israeli scientists find promising target for breast cancer and other cancer therapeutics

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Alkem’s St Louis facility gets two observations from US FDA | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Hexafluorodianhydride(6-FDA)

Hexafluorodianhydride(6-FDA)
Vinorelbine tartrate (FDA)

Vinorelbine tartrate (FDA)
High quality Stability Chamber(FS/CFS Series:FDA)

High quality Stability Chamber(FS/CFS Series:FDA)
Etoposide( FDA)

Etoposide( FDA)
Hemisuccinate /Sodium (FDA/DMF)

Hemisuccinate /Sodium (FDA/DMF)
GMP/FDA/ISO grade cleanroom system for pharmaceutical cleanroom project

GMP/FDA/ISO grade cleanroom system for pharmaceutical cleanroom project
Ivermectin (FDA)

Ivermectin (FDA)
Daunomycin HCL( FDA)

Daunomycin HCL( FDA)
Ramantadine( FDA)

Ramantadine( FDA)
Tobramycin base( FDA)

Tobramycin base( FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service